Endovascular treatment of a renal artery stenosis: techniques, indications, results. Role of embolic protection devices (part 2).
Henry
M
M
Cabinet de Cardiologie, Nancy, France. m.henryilrmdt@wanadoo.fr
Henry
I
I
Polydorou
A
A
Polydorou
Ad
A
Hugel
M
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002404:Catheterization / Q000295:instrumentation* / Q000379:methods; D000077144:Clopidogrel; D004617:Embolism / Q000517:prevention & control*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006629:Hirudins; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012078:Renal Artery Obstruction / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005343:Fibrinolytic Agents; D006629:Hirudins; D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D006493:Heparin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin; C074619:bivalirudin